OTCQB: GTBP

Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline

About

GT Biopharma, Inc. a targeted immunotherapies company.

About

Latest News

GT Biopharma Appoints Two New Independent Directors
Jan 19, 2021 • 9:00 EST | Read More

GT Biopharma Announces Eighth Patient Begins Treatment Of GTB-3550
Jan 12, 2021 • 10:00 EST | Read More

Investors

GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range